CABALETTA BIO, INC. Total Liabilities and Equity
CABALETTA BIO, INC. (CABA) had Total Liabilities and Equity of $256.73 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-13
- 2026-06-30: Liabilities and Equity $256.73M.
- 2026-03-31: Liabilities and Equity $148.15M.
- 2025-12-31: Liabilities and Equity $165.08M.
- 2025-09-30: Liabilities and Equity $189.76M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $256.73M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $148.15M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $165.08M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $189.76M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $224.50M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $165.14M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $185.05M 10-K · filed 2026-03-23 |
| 2024-09-30 | $204.41M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $217.42M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $240.46M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $253.65M 10-K · filed 2025-03-31 |
| 2023-09-30 | $173.29M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $184.64M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $103.45M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $116.97M 10-K · filed 2024-03-21 |
| 2022-09-30 | $91.67M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $102.02M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $113.66M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $126.34M 10-K · filed 2023-03-16 |
| 2021-09-30 | $122.64M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $106.93M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $107.28M 10-Q · filed 2021-05-03 |
| 2020-12-31 | $114.72M 10-K · filed 2022-03-17 |
| 2020-09-30 | $121.77M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $127.90M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $134.97M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $141.47M 10-K · filed 2021-03-16 |
| 2019-09-30 | $74.94M 10-Q · filed 2019-12-05 |
| 2018-12-31 | $34.17M 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |